# BIBW 2992 Administered as Tablet (Final Formulation) Compared to BIBW 2992 Drinking Solution and BIBW 2992 Tablet (Trial Formulation II) in Healthy Male Volunteers

> **NCT02171715** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 22 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BIBW 2992 MA2
- **DRUG:** BIBW 2992 MA2
- **DRUG:** BIBW 2992 MA2

## Key facts

- **NCT ID:** NCT02171715
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2009-04
- **Final completion:** —
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2014-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02171715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02171715, "BIBW 2992 Administered as Tablet (Final Formulation) Compared to BIBW 2992 Drinking Solution and BIBW 2992 Tablet (Trial Formulation II) in Healthy Male Volunteers". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT02171715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*